References
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.
Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw. 2018;16(6):693–702.
Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64.
Schmitz R, Mao R, Moris D, et al. Impact of postoperative chemotherapy on survival of patients with high-grade gastroenteropancreatic neuroendocrine carcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08730-0.
Mao R, Li K, Cai JQ, et al. Adjuvant chemotherapy versus observation following resection for patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003562.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Schmitz, R., Moris, D., Strickler, J.H. et al. ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. Ann Surg Oncol 27 (Suppl 3), 804–805 (2020). https://doi.org/10.1245/s10434-020-08802-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08802-1